India rejects application to extend patent on TB drug bedaquiline

BMJ. 2023 Mar 28:380:724. doi: 10.1136/bmj.p724.
No abstract available

MeSH terms

  • Antitubercular Agents / therapeutic use
  • Diarylquinolines* / therapeutic use
  • Humans
  • India
  • Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

  • bedaquiline
  • Diarylquinolines
  • Antitubercular Agents